The beachhead choice. One clear path over several uncertain ones.
Six months into an NHS product launch. Forty-plus conversations started. Representatives attending three or four conferences a quarter. A CRM full of contacts across nine specialties in four regions.
And almost nothing closed.
The pipeline review reveals a long list of entries marked "in discussion" and "showing interest." The commercial director wants to know what happened to the accounts that were "looking promising" in Q2. The team cannot quite say. The conversations were real and the interest was genuine, yet the pipeline, somehow, has not moved.
This is not unusual. It is, by a significant margin, the most common version of year one in an NHS product launch.
Why the National Approach Feels Right
When a medtech company prepares to launch into the NHS, the planning process almost always reaches the same conclusion. Identify every trust and clinical setting where the product could theoretically be used, and start building relationships across all of them simultaneously.
The logic holds on paper. You are launching into a national health system. The market is, theoretically, every acute trust in the country. With a product that could benefit patients across general surgery, interventional radiology, and vascular care, limiting yourself to one speciality or one geography feels like leaving revenue on the table. The conference circuit exists precisely for this reason. Gather as many contacts as possible across the full market and begin warming them simultaneously.
Sales directors are rarely wrong to push for scale. A narrow launch looks modest in a board presentation. A national outreach plan looks ambitious. Investors, management teams, and the commercial leads themselves tend to be rewarded for coverage, not concentration.
(Ask me how I know. I spent a fair amount of time presenting slide decks that said "we have pipeline in eighteen trusts" without mentioning that exactly one of them was actually progressing.)
The appeal of the broad approach extends into the conference budget as well. If you attend every major event in your speciality, you generate visibility across the market. Awareness creates interest, and interest creates pipeline. Or so the argument goes.
The logic is reasonable. The outcome is reliably disappointing.
The NHS Does Not Have a National Buying Decision
Each NHS trust runs its own procurement process. There is no central buying authority for most clinical products.
The structural problem is that the NHS buying environment does not work the way a national outreach plan assumes.
There is no central procurement authority for the majority of clinical products. Each NHS trust runs its own formulary and approved product list process, with its own clinical governance committee, its own innovation panel, and its own set of internal decision-making dynamics. A product endorsed by a clinical champion at one trust has essentially no influence on the decision-making process at the trust fifteen miles away.
This is not an obstacle to be worked around. It is simply how the system operates.
And it has significant implications for how you should allocate effort in year one.
The most common failure mode looks like this. A commercial team spreads its effort across thirty or forty trusts simultaneously, running light-touch conversations at each site. The conversations are real. The contacts are genuine. But no individual trust receives enough concentrated attention to move from interest to clinical evaluation to procurement approval.
Clinical champion development is the central requirement for an NHS product launch. It requires a clinician who not only believes in the product but has the credibility, motivation, and institutional knowledge to move their trust's internal approval process forward on the product's behalf. Building that relationship to the point where it becomes commercially productive typically takes twelve to eighteen months of consistent, substantive engagement.
When that engagement is spread across forty sites instead of four, no individual champion relationship reaches the depth that closes an account. The rep attends the conference, has the conversation, follows up twice, and moves on to the next site. The champion at Trust A files it under "interesting developments" and moves on too.
(The conference becomes a source of new names to add to the list of trusts that are "showing interest." The list grows. The pipeline does not.)
There is a compounding effect worth noting. The spread-and-shallow approach makes it very difficult to build a proof case. When the question eventually comes from trust seventeen about whether the product actually works in an NHS clinical setting, the honest answer is that you have had positive conversations at other sites but have not yet generated the clinical outcomes data that a procurement committee will ask for.
The question tends to go quiet after that.
You Are Confusing Activity with Traction
The reframe that most NHS launch teams resist is this. In the early stages of a launch, breadth and traction are inversely related.
The broader your outreach, the thinner your engagement at each site. The thinner your engagement, the less likely any individual site moves through procurement. The less any individual site moves, the weaker your proof case becomes for all subsequent sites.
What you are building, inadvertently, is the appearance of momentum without the substance of it.
Traction in the NHS context means something specific. It means a clinical champion who has publicly advocated for the product internally. A procurement pathway that is actively moving, with a timeline and a named decision-maker. And clinical outcomes data from that trust's patient population.
These are the things that make trust number two significantly faster to close than trust number one.
The beachhead concept, borrowed from military strategy, is directly applicable here. A beachhead is a small, defined position from which you can expand. You do not try to take the entire coastline on day one. You find the position where your odds are highest, establish it as a secure base, and move from a position of demonstrated strength rather than scattered hope.
For an NHS product launch, the beachhead is your first trust. The one where the clinical champion is most engaged, the procurement pathway is most navigable, and the patient population most closely matches your evidence base. You put everything there.
Not because the other trusts do not matter. Because the proof case you build in trust one is what makes all the other trusts possible.
("Start focused" sounds like tactical humility. What it actually is is the thing that gets you to scale faster. Which is not obvious until you have watched it play out several times.)
One Trust. Prove the Model. Then Move.
The four-stage beachhead sequence for NHS product launch.
The beachhead method for NHS product launches has four stages.
Start with site selection, not market mapping.
The first question is not "which specialities can use this product?" The first question is "which single trust has the conditions that make a successful first close most likely?"
Those conditions include a clinical champion who has already expressed genuine interest, a procurement process that is navigable without requiring a structural change at the trust, a patient cohort that closely matches your evidence base, and an unmet clinical need that is actively causing problems for that team.
You are not looking for the biggest trust or the most prestigious one. You are looking for the one where the conditions are most favourable. This is, deliberately, choosing where to win rather than trying to win everywhere.
Build that relationship with unusual depth.
Once the first trust is selected, the engagement model looks quite different from the conventional conference circuit approach. The clinical rep attends clinical meetings, not just healthcare conferences. The champion is supported in presenting the product to their colleagues. The trust's specific patient pathway is mapped. The evidence that will satisfy that trust's particular clinical governance process is assembled in advance.
This takes longer in the short term than spreading across thirty trusts simultaneously. It takes less time in the long term, because trust two gets a proven model rather than a cold start.
Build the evidence that makes trust two faster.
The beachhead trust is not just a revenue target. It is a proof case. The clinical outcomes data from trust one becomes the most powerful piece of commercial evidence you have for trust two. The procurement pathway documentation from trust one becomes a template. The clinical champion from trust one becomes a peer reference for the champion at trust two.
Every piece of work done in the first trust compounds into an asset that accelerates the second, and the third.
Scale once the model is repeatable.
The signal to expand is not twelve months on the calendar. It is a documented, repeatable model. You know how to find the right champion, you understand this procurement process end to end, you have the clinical outcomes data, and trust one has moved from evaluation to committed use.
Mind you, the pressure to expand before the model is genuinely repeatable is significant. Boards want to see a national footprint. The answer to that pressure is not to hold the line forever, but to be specific about what you need from the beachhead before you move on.
What Happened When They Stopped Trying to Win Everywhere
Concentration over coverage. The commercial shift that changed the launch trajectory.
A mid-sized medtech company in the endovascular space came to us twelve months into their NHS launch. The technology was clinically strong, the published evidence base solid, the clinical need genuine.
They had identified 85 trusts across three specialities where the product could theoretically be used. The commercial team had attended six national conferences, started conversations at 34 sites, and built a CRM that classified 28 of those sites as "active." None had closed.
(The team's morale, at that point, was not strong. That is the polite version.)
We ran a site-selection exercise across their 28 "active" accounts, assessing each against five criteria. Clinical champion depth, procurement navigability, patient cohort match, intensity of unmet clinical need, and absence of a competing product already in use.
Three trusts met all five criteria. We recommended stopping all other active outreach and concentrating commercial activity on those three sites.
Six months later, two of the three had submitted for formal clinical evaluation. Fourteen months after the shift, both had closed. A third trust opened on the basis of a published outcomes case study from trust one.
The commercial director described the shift as "uncomfortably slow for three months, and then faster than anything we had seen before."
That is a fair account of what a beachhead strategy feels like to live through.
Where to Start Tomorrow
Score each of your current sites against five criteria. The highest-scoring trust is your beachhead.
The shift to a beachhead strategy does not require starting over. If you already have existing relationships at multiple trusts, the first step is a site-selection audit.
For each trust in your current pipeline, score it out of three on five criteria.
- Clinical champion depth. Would this person go to bat for the product at their next committee meeting?
- Procurement navigability. Do you understand the pathway from evaluation to first clinical use?
- Patient cohort match. Does the trust's patient population closely match your evidence base?
- Unmet clinical need. Is there a problem that is actively costing this team something right now?
- Competitive absence. Is there no comparable product already in routine clinical use?
The trust with the highest total score is your beachhead. Re-allocate the majority of commercial activity there. Keep light-touch contact with others, but do not count light-touch contact as active pipeline management.
In the beachhead trust, commit to clinical champion development as the primary activity. This means attending clinical meetings rather than just presenting the product. It means understanding the champion's internal advocacy challenges and helping to address them. It means co-developing the outcomes data presentation that will satisfy the clinical governance committee.
Fair enough if this feels like a significant change to the existing plan. It usually does.
The useful question to ask before continuing on the current path is. How many of the current pipeline sites are actually moving, and at what speed?
If the honest answer is "most are not moving much," the beachhead approach is not a retreat. It is a more direct route to the same destination.
Why This Matters Beyond the Pipeline Number
Somewhere in the NHS, there are patients whose condition would respond to your product. Clinicians who know this and cannot get procurement approval because the evidence base has not been assembled in their trust's format. Patients waiting because the commercial strategy did not concentrate long enough to close the first account.
The launch that spreads widest and fastest does not reach those patients. The launch that proves itself in one trust, builds the clinical outcomes evidence, and then replicates that proof to the next trust does.
The beachhead is not a conservative strategy. It is the strategy that actually gets the product to the patients who need it.
Start there.
Start with One. The NHS Beachhead Launch Diagnostic.
A practical five-criteria scoring tool for healthcare commercial teams. Identify your beachhead trust, build the proof case, and move from a position of strength.
Run the free launch readiness assessment
SUBSCRIBE: Weekly Insights on Healthcare Demand Generation
Delivered every week. No spam.
About Michael Colling-Tuck
Michael is the founder of AGENCY, a demand generation consultancy that helps MedTech, Pharma, and Diagnostics companies build the systems that drive commercial success. He is the author of It's Not a Sales Problem.
After 47 product launches across healthcare, he works with companies at the commercial stage of their growth, helping them build demand rather than manage activity.
Podcast: https://agencymedicalmarketing.com/podcast
References
- NHS England. (2023). Accelerated Access Collaborative: Adoption and Spread Framework. NHS England Transformation Directorate.
- ABHI. (2024). Medtech Market Access in the NHS: Commercial Pathways Guide. Association of British HealthTech Industries.
What next?